Option chain shows key data for Tevogen Bio Holdings's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Tevogen Bio Holdings.

Tevogen Bio Holdings (NASDAQ:TVGN) Stock, Option Chain

TEVOGEN BIO HOLDINGS INC

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

biotech shutter

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

TVGN

D Boral Capital initiates Buy on Tevogen Bio citing its scalable T-cell therapies and upcoming clinical readouts, with a $10 price target.

Tevogen Bio&#39;s T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential

Analysts expect Ford Motor Co. (NYSE: F) to post quarterly earnings at 33 cents per share on revenue of $43.25 billion after the closing bell. Ford shares fell 0.7% to $10.09 in after-hours trading.

Markets

TTAM

This Tevogen Bio Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

benzingaai2023_stock_market_trading_setup_close_up_of_multipl_9ea2f44f-9171-417b-a64e-58bbbd995de1_0

Contracts

MSFT

Tevogen Bio Holdings Inc (NASDAQ:TVGN) shares are trading higher Monday after the company announced an expanded AI collaboration with Microsoft Corp (NASDAQ:MSFT).

What&#39;s Going On With Tevogen Bio Stock Today?

Tevogen Bio Holdings Inc

Management

Press Releases

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity

Financing

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel

Legal

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

TVGNW

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Amarin Corp

Annexon

Cidara Therapeutics

Cardiff Oncology

Cargo Therapeutics

Design Therapeutics

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Foghorn Therapeutics

Genfit

Gossamer Bio

TuHURA Biosciences

INmune Bio

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Inventiva S.A. - American Depository Shares

Inventiva

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Nanobiotix

Nuvectis Pharma

Ocugen

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Prime Medicine

Rezolute

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

D. Boral Capital

Comments

Tevogen Bio Holdings

Tevogen Bio Holdings (TVGN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga